Unlikely. I think it's more to do with this: Synthon will host a call to discuss data from its EU comparative trial for its generic Copaxone on Mar.27 [via MS]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.